Abstract

Eyubova Ulviyya Aladdin1, Murad Bakhshiyev 2, Gunay Rahimova3 and Ata Kirilmaz4

Background: Modern principles of current treatment techniques are based on the pathogenic concept that develops as a result of the long-term activation of the CHF neurohormonal system. The essence of such a concept is quite simple, the higher the degree of different levels of neurohumoral regulation, the better the result. At present the inhibitor of neprilysin is widely used in the treatment of CHF in the world practice.

The aim: Our study has been conducted in the form of 2 groups. The first group consists of the patients treated with complex medical therapy including sacubitril / valsartan. And the second group consists of the patients implanted a device for resynchronous therapy of the heart. Our aim is to assess the changes in the clinical indicators in both groups after 6 months.

Materials and methods: The results of 64 male and female with CHF were researched. Patients were over 38 years of age. Eligibility criteria included a history of chronic heart failure, circulatory failure (functional class II-IV, NHYA) and a left ventricular ejection fraction of less than 40%. Exclusion criteria included acute myocardial infarction, hypertrophic cardiomyopathy, congenital heart defects, patients under 25 years of age, heart failure in oncological patients. Results of our study: At the time of re-examination after 6 months, there is a positive change in the clinical indicators of patients, includings systolic blood pressure, diastolic blood pressure, pulse, complaints during physical activity, functional classes and ejection fraction of left ventricul in both groups.

Conclusion: The results of both treatments have been compared both medically and economically. From a medical point of view, in results, the difference was small. From a medical point of view, in results, the difference was small. So that in results of frist group many indicators was better than second group results. But results of some indicators was same in both groups. However, from an economic point of view, device treatment is often expensive.